Frontiers in Cardiovascular Medicine · 2022 · 11 citations · 10 references
MedicineCardiologyOncologyCardio-oncologyChemotherapyGastrointestinal OncologyCancer Therapy-related CardiotoxicityCardiac PharmacotherapyCardiotoxicity ManagementCardiovascular Drug SafetyOncology PharmacologyAcute Cardiac ToxicityAnticancer ChemotherapyCardiac Monitoring During Cancer TherapyCardiotoxicityDiltiazem TherapyNon-st-elevation Myocardial InfarctionPermanent Pacemaker TherapyThird-degree Atrioventricular Block
Background: The adverse effects of anticancer therapy in patients with malignancies and cardiovascular diseases are complicated. Oxaliplatin is one of the most commonly used chemotherapy drugs for gastric and colorectal cancers, and oxaliplatin-induced cardiotoxicity has rarely been reported. Case Summary: We report a 76-year-old man with adenocarcinoma of the esophagogastric junction and a 40-day history of non-ST-elevation myocardial infarction who exhibited a new third-degree atrioventricular block after oxaliplatin administration. We immediately withdrew oxaliplatin treatment and, to avoid future episodes, we implanted a permanent pacemaker for safety and added diltiazem hydrochloride. The third-degree atrioventricular block disappeared after oxaliplatin withdrawal. We detected no recurrence of the third-degree atrioventricular block in future chemotherapies. Conclusions: This is the first reported oxaliplatin-induced third-degree atrioventricular block, likely mediated by coronary artery spasm. Cancer patients with acute coronary syndrome are a unique and vulnerable population, whom physicians should carefully evaluate and monitor during anticancer treatment. Remarkably, even the most common chemotherapy drugs can cause life-threatening cardiac adverse events.
10
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Angina pectoris I. A variant form of angina pectoris
Myron Prinzmetal, Rexford Kennamer, R. R. Merliss et al. · The American Journal of Medicine · 1959 · 1.5K citations
Oxaliplatin: mechanism of action and antineoplastic activity.
Éric Raymond, Sandrine Faivre, Jan M. Woynarowski et al. · PubMed · 1998 · 523 citations
Medicine, Oncology, Pharmacology +12
Oxaliplatin‐induced neurotoxicity and the development of neuropathy
Arun V. Krishnan, David Goldstein, Michael Friedländer et al. · Muscle & Nerve · 2005 · 214 citations
Medicine, Neurology, Pharmacology +16